Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum:: Genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites

被引:185
作者
Nzila, AM
Mberu, EK
Sulo, J
Dayo, H
Winstanley, PA
Sibley, CH
Watkins, WM
机构
[1] Kenya Med Res Inst, Wellcome Trust Res Labs, Wellcome Trust Collaborat Res Program, Nairobi, Kenya
[2] Kenya Med Res Inst, Ctr Geog Med Res, Kilifi, Kenya
[3] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3BX, Merseyside, England
[4] Univ Washington, Dept Genet, Seattle, WA 98195 USA
基金
英国惠康基金;
关键词
D O I
10.1128/AAC.44.4.991-996.2000
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The antifolate combination of pyrimethamine (PM) and sulfadoxine (SD) is the last affordable drug combination available for wide-scale treatment of falciparum malaria in Africa. Wherever this combination has been used, drug-resistant parasites have been selected rapidly. A study of PM-SD effectiveness carried out between 1997 and 1999 at Kilifi on the Kenyan coast has shown the emergence of RI and RII resistance to PM-SD (residual parasitemia 7 days after treatment) in 39 out of 240 (16.25%) patients. To understand the mechanism that underlies resistance to PM-SD, we have analyzed the dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) genotypes of 81 patients. Fifty one samples were obtained, before treatment, from patients who remained parasite free for at least 7 days after treatment. For a further 20 patients, samples were obtained before treatment and again when they returned to the clinic with parasites 7 days after PM-SD treatment. Ten additional isolates were obtained from patients who were parasitemic 7 days after treatment but who were not sampled before treatment. More than 65% of the isolates (30 of 46) in the initial group had wild-type or double mutant DHFR alleles, and all but 7 of the 47 (85%) had wild-type DHPS alleles. In the paired (before and after treatment) samples, the predominant combinations of DHFR and DHPS alleles before treatment were of triple mutant DHFR and double mutant DHPS (41% [7 of 17]) and of double mutant DHFR and double mutant DHPS (29% [5 of 17]). All except one of the posttreatment isolates had triple mutations in DHFR, and most of these were "pure" triple mutants. In these isolates, the combination of a triple mutant DHFR and wild type DHPS was detected in 6 of 29 cases (20.7%), the combination of a triple mutant DHFR and a single mutant (A437G) DHPS was detected in 4 of 29 cases (13.8%), and the combination of a triple mutant DHFR and a double mutant (A437G, L540E) DHPS was detected in 16 of 29 cases (55.2%). These results demonstrate that the triply mutated allele of DHFR with or without mutant DHPS alleles is associated with RI and RII resistance to PM-SD. The prevalence of the triple mutant DHFR-double mutant DHPS combination may be an operationally useful marker far predicting the effectiveness of PM-SD as a new malaria treatment.
引用
收藏
页码:991 / 996
页数:6
相关论文
共 39 条
[1]   Chlorproguanil-dapsone: Effective treatment for uncomplicated falciparum malaria [J].
Amukoye, E ;
Winstanley, PA ;
Watkins, WM ;
Snow, RW ;
Hatcher, J ;
Mosobo, M ;
Ngumbao, E ;
Lowe, B ;
Ton, M ;
Minyiri, G ;
Marsh, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (10) :2261-2264
[2]   POINT MUTATIONS IN THE DIHYDROFOLATE-REDUCTASE THYMIDYLATE SYNTHASE GENE AND PYRIMETHAMINE AND CYCLOGUANIL RESISTANCE IN PLASMODIUM-FALCIPARUM [J].
BASCO, LK ;
DEPECOULAS, PE ;
WILSON, CM ;
LEBRAS, J ;
MAZABRAUD, A .
MOLECULAR AND BIOCHEMICAL PARASITOLOGY, 1995, 69 (01) :135-138
[3]   Molecular epidemiology of malaria in Yaounde, Cameroon II.: Baseline frequency of point mutations in the dihydropteroate synthase gene of Plasmodium falciparum [J].
Basco, LK ;
Ringwald, P .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1998, 58 (03) :374-377
[4]   Molecular basis of in vivo resistance to sulfadoxine-pyrimethamine in African adult patients infected with Plasmodium falciparum malaria parasites [J].
Basco, LK ;
Tahar, R ;
Ringwald, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (07) :1811-1814
[5]   BEYOND CHLOROQUINE - IMPLICATIONS OF DRUG-RESISTANCE FOR EVALUATING MALARIA THERAPY EFFICACY AND TREATMENT POLICY IN AFRICA [J].
BLOLAND, PB ;
LACKRITZ, EM ;
KAZEMBE, PN ;
WERE, JBO ;
STEKETEE, R ;
CAMPBELL, CC .
JOURNAL OF INFECTIOUS DISEASES, 1993, 167 (04) :932-937
[6]   SEQUENCE VARIATION OF THE HYDROXYMETHYLDIHYDROPTERIN PYROPHOSPHOKINASE - DIHYDROPTEROATE SYNTHASE GENE IN-LINE SO THE HUMAN MALARIA PARASITE, PLASMODIUM-FALCIPARUM, WITH DIFFERING RESISTANCE TO SULFADOXINE [J].
BROOKS, DR ;
WANG, P ;
READ, M ;
WATKINS, WM ;
SIMS, PFG ;
HYDE, JE .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1994, 224 (02) :397-405
[7]   MOLECULAR-CLONING AND SEQUENCE-ANALYSIS OF THE PLASMODIUM-FALCIPARUM DIHYDROFOLATE-REDUCTASE THYMIDYLATE SYNTHASE GENE [J].
BZIK, DJ ;
LI, WB ;
HORII, T ;
INSELBURG, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (23) :8360-8364
[8]   AMINO-ACID CHANGES LINKED TO PYRIMETHAMINE RESISTANCE IN THE DIHYDROFOLATE-REDUCTASE THYMIDYLATE SYNTHASE GENE OF PLASMODIUM-FALCIPARUM [J].
COWMAN, AF ;
MORRY, MJ ;
BIGGS, BA ;
CROSS, GAM ;
FOOTE, SJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (23) :9109-9113
[9]   In vivo selection for a specific genotype of dihydropteroate synthetase of Plasmodium falciparum by pyrimethamine-sulfadoxine but not chlorproguanil-dapsone treatment [J].
Curtis, J ;
Duraisingh, MT ;
Warhurst, DC .
JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (05) :1429-1433
[10]   Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali [J].
Diourté, Y ;
Djimdé, A ;
Doumbo, OK ;
Sagara, I ;
Coulibaly, Y ;
Dicko, A ;
Diallo, M ;
Diakité, M ;
Cortese, JF ;
Plowe, CV .
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1999, 60 (03) :475-478